If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-yearly Report

27 Nov 2009 07:00

27 November 2009 Sterling Green Group Plc ("Sterling Green" or "the Company") Half-yearly results for the six month period ended 30 September 2009 Highlights * Revenue from debt management services increased by 54 per cent. to 1,052,000 * Operating profit of 55,000 from debt management services * Operating profit of 14,000 from the mortgage division despite 65 per cent. fall in revenues. * Significant increase in active client numbers to 3,120 Enquiries:Sterling Green Group plc Tel: 0161 975 5757 Michael Edelson Merchant John East Securities Limited Tel: 020 7628 2200 Simon Clements/David Worlidge

Chairman's Statement

Introduction

I am pleased to present the Group's half-yearly results for the six month period ended 30 September 2009.

Results and dividends

The Group generated a loss before and after taxation for the six month period of 41,000 (six months ended 30 September 2008 - 365,000 loss) on revenues of 1,139,000 (six months ended 30 September 2008 - 931,000).

The Directors do not recommend the payment of a dividend.

Trading review

The Group started the current financial year as a much more streamlined business. Revenues from debt management services for the six month period ended 30 September 2009 were 1,052,000 compared to 681,000 for the six month period ended 30 September 2008, representing a 54 per cent. increase. The increased revenues generated an operating profit for debt management services of 55,000 compared to an operating loss of 242,000 for the six month period ended 30 September 2008. The Directors are encouraged by the improvement in the financial performance of the debt management division during the period.

In contrast, the results from the mortgage division were disappointing. Re-mortgage commission revenues in the period were 87,000 compared to 250,000 for the six month period ended 30 September 2008. Despite the reduction in revenue, the mortgage division did generate an operating profit of 14,000 reflecting an improvement compared to the 25,000 operating loss for the six month period ended 30 September 2008. This improvement in operating result reflected a significant reduction in the staff costs and other operational overheads of the division.

The level of unallocated central Group costs in the period remained consistent with the prior period.

The Group had 3,120 active debt management clients as at 30 September 2009, representing an increase of 577 in the period.

Going concern

There have been no significant changes in the going concern status of the Group since the release of the audited financial statements for the year ended 31 March 2009. Accordingly, the Board has prepared this half-yearly financial report on the going concern basis.

Outlook

The Board is pleased with the increase in the number of debt management clients and associated growth in revenues in the period and are confident that the business will continue to grow in the second half of the year, albeit at a slower rate. In order to sustain the Group's growth momentum, the Board continues to review opportunities which have the potential to provide additional revenue streams. In particular, the Board is seeking potential introducers of new business. Furthermore, the Board continue to seek out potential acquisition targets in the area of small debt management business and debt management portfolios.

Michael EdelsonChairman26 November 2009

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2009

Six months e Six months Year nded 30 ended 30 September September ended 2009 2008 31March 2009 GBP000 GBP000 GBP000 Revenue 1,139 931 1,966 Cost of sales (557) (616) (1,069) Gross profit 582 315 897 Administrative expenses (600) (667) (1,218) Results from operating activities (18) (352) (321) Finance income - 4 5 Finance costs (23) (17) (49) Net finance costs (23) (13) (44) Loss on ordinary activities before (41) (365) (365)taxation Income tax credit - - 18 Loss on ordinary activities after (41) (365) (347)taxation attributable to equity holders of the parent Loss per share - basic and diluted (0.01p) (0.13p) (0.12p)

All amounts relate to continuing operations.

All comprehensive income is attributable to the equity holders of the parent.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY

FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2009

Six months Six months Year ended 30 ended 30 September 200 September ended 31 9 2008 March 2009 GBP000 GBP000 GBP000 Balance at the beginning of the period 925 972 972 Total comprehensive income for the period Loss for the period (41) (365) (347) Transactions with owners Issue of share capital 100 200 200 Share capital to be issued (100) - 100 Total transactions with owners - 200 300 Balance at the end of the period 884 807 925

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 SEPTEMBER 2009 As at 30 As at As at September 200 9 30 September 31 March 2008 2009 GBP000 GBP000 GBP000 Non-current assets Goodwill 1,115 1,115 1,115 Property, plant and equipment 161 258 209 Total non-current assets 1,276 1,373 1,324 Current assets Trade and other receivables 235 89 142 Cash and cash equivalents 97 102 182 Total current assets 332 191 324 Total assets 1,608 1,564 1,648 Current liabilities Trade and other payables (364) (342) (319) Current tax liabilities - (18) - Borrowings (86) (86) (86) Total current liabilities (450) (446) (405) Net current liabilities (118) (255) (81) Non-current liabilities Loans and borrowings (274) (311) (318) Total non-current liabilities (274) (311) (318) Total liabilities (724) (757) (723) Net assets 884 807 925 Equity Share capital 304 288 288 Share premium account 1,794 1,710 1,710 Share capital to be issued - - 100 Capital reserve 6 6 6 Other reserves 891 891 891 Retained losses (2,111) (2,088) (2,070) Total equity 884 807 925

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW

FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2009

Six months Six months Year ended 30 ended 30 ended 31 September September March 2009 2008 2009 GBP000 GBP000 GBP000 Cash flows used in operating activities Loss before tax (41) (365) (365) Adjustments for: Depreciation of property, plant and 49 52 101equipment Finance income - (4) (5) Finance costs 23 17 49 Operating cash flows before movement 31 (300) (220)in working capital (Increase)/ Decrease in trade and (93) 52 (1)other receivables Increase in trade and other payables 45 24 1

Net cash used in operating activities (17) (224) (220)

Cash flow (used in)/generated from investing activities Purchase of property, plant and (1) (1) (1)equipment Finance income - 4 5 Net cash (used in)/generated from inve (1) 3 4sting activities Cash flow (used in)/generated from financing activities Capital element of finance lease (44) (42) (85)payments Issue of ordinary share capital, net - 200 200of costs Proceeds from new loans - 200 250 Proceeds in advance of issue of share - - 100capital Finance costs (23) (17) (49) Net cash (used in)/generated from (67) 341 416financing activities Net (decrease)/increase in cash and (85) 120 200cash equivalents Cash and cash equivalents at beginning 182 (18) (18)of period Cash and cash equivalents at end of 97 102 182period

NOTES TO THE HALF-YEARLY REPORT

FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2009

1. Reporting entity

Sterling Green Group plc (the "Company") is a company registered in England and Wales. The condensed consolidated interim financial statements of the Company for the six month period ended 30 September 2009 comprise the Company and its subsidiaries (together the "Group").

The consolidated financial statements of the Group for the year ended 31 March 2009 are available upon request from the Company's registered office by writing to the Company Secretary, Sterling Green Group plc, Number 14, The Embankment, Vale Road, Heaton Mersey, Stockport SK4 3GN or can be obtained from the Company's website which is www.sterlinggreen.co.uk.

2. Statement of compliance

This interim financial report has been prepared on the basis of the recognition and measurement requirements of IFRS anticipated to be in issue as either endorsed by the EU and effective (or available for early adoption) at 31 March 2010.

This interim financial report should be read in conjunction with the Report and Accounts for the year ended 31 March 2009, which were approved for issue by the Board of Directors on 29 September 2009, as it provides an update of previously reported information.

The comparative figures for the year ended 31 March 2009 were derived from the statutory accounts for that year which have been delivered to the Registrar of Companies. Those accounts received an unqualified audit report which did not contain statements under sections 498 (2) or (3) of the Companies Act 2006.

These condensed consolidated interim financial statements were approved by the Board on 26 November 2009. The financial information contained therein for the six month period ended 30 September 2009 and similarly the six month period ended 30 September 2008 has neither been audited nor reviewed.

3. Operating segments

The Group's business segments are its debt management division, its re-mortgaging operations and its head office operations. This is the basis on which the Group reports its primary segmental information. In the table below, all revenues are generated by sales to external parties.

Debt Re- Unallocated Total Manage- mortgages Group items ment GBP000 GBP000 GBP000 GBP000 Performance by activity: Revenue: - six months ended 30 Sept 1,052 87 - 1,1392009 - six months ended 30 Sept 681 250 - 9312008 - year ended 31 March 2009 1,609 357 - 1,966 Operating profit/(loss): - six months ended 30 Sept 55 14 (87) (18)2009 - six months ended 30 Sept (242) (25) (85) (352)2008 - year ended 31 March 2009 (168) 15 (168) (321) Total assets: - 30 September 2009 1,563 25 20 1,608 - 30 September 2008 1,448 16 100 1,564 - 31 March 2009 1,524 22 102 1,648

The Group operates in a sector where no significant seasonal or cyclical variations in revenues and operating results are experienced during the financial year.

4. Loss per share

The calculation of basic loss per share is based on the following:

Six months Six months Year ended ended 30 ended 30 31 September September March 2009 2008 2009 Loss for the period ( 000) (41) (365) (347) Weighted average number of 303,500,527 287,844,242 287,569,637shares Loss per share (pence) (0.01) (0.13) (0.12)

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares in issue assuming conversion of all dilutive potential ordinary shares. The Company's potential ordinary shares consist of share options, warrants and deferred consideration. Due to losses in the current and preceding periods there are no dilutive ordinary shares.

5. Dividends

No dividend is proposed for the six month period ended 30 September 2009. No dividend was paid in or proposed for the year ended 31 March 2009.

vendor
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.